These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25512414)

  • 21. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.
    Goncalves-Pereira J; Silva NE; Mateus A; Pinho C; Povoa P
    BMC Pharmacol Toxicol; 2014 Apr; 15():21. PubMed ID: 24731745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-Informed Therapeutic Drug Monitoring of Meropenem in Critically Ill Patients: Improvement of the Predictive Ability of Literature Models with the PRIOR Approach.
    Chan Kwong A; O'Jeanson A; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):415-426. PubMed ID: 33830470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
    Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
    J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
    Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
    Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic properties of meropenem.
    Nicolau DP
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates.
    Nehus EJ; Mouksassi S; Vinks AA; Goldstein S
    J Clin Pharmacol; 2014 Dec; 54(12):1421-8. PubMed ID: 25042683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
    Deshpande P; Chen J; Gofran A; Murea M; Golestaneh L
    Nephrol Dial Transplant; 2010 Aug; 25(8):2632-6. PubMed ID: 20181801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
    Tam VH; Schilling AN; Poole K; Nikolaou M
    J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
    Tröger U; Drust A; Martens-Lobenhoffer J; Tanev I; Braun-Dullaeus RC; Bode-Böger SM
    Int J Antimicrob Agents; 2012 Oct; 40(4):370-2. PubMed ID: 22795654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
    Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
    Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.